Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
14 Jun, 2017 | 00:43h | UTCCommentary: CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations – Medscape (free registration required)
Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation and fractures. The benefits and harms were likely small. See interesting commentaries on the trade-offs by @AnilMakam, see Tweet 1; Tweet 2; Tweet 3; Tweet 4; Tweet 5; Tweet 6; Tweet 7; Tweet 8; and Tweet 9.